Resurrection of PARP Inhibitors in Breast Cancer

被引：16
|
作者：
Lyons, Tomas G. [1 ]
Robson, Mark E. [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Breast Med Serv, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, 1275 York Ave, New York, NY 10065 USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2018年 / 16卷 / 09期
关键词：
RECURRENT OVARIAN-CANCER; GERMLINE BRCA MUTATION; PHASE-I; POLY(ADP-RIBOSE) POLYMERASE; SOLID TUMORS; MAINTENANCE THERAPY; DNA-DAMAGE; OPEN-LABEL; OLAPARIB; CARBOPLATIN;
D O I：
10.6004/jnccn.2018.7031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PARP enzymes are essential for DNA damage repair. Cancers with defective homologous recombination DNA repair, such has BRCA1-and BRCA2-mutated breast cancers, are targets for PARP inhibitors (PARPi) through the exploitation of synthetic lethality. A number of PARPi are currently undergoing clinical evaluation in breast cancer, with olaparib and talazoparib having demonstrated superior efficacy compared with standard chemotherapy in advanced germline BRCA-mutated cancer. This review describes the biological rationale for PARPi and presents the accumulating data on PARPi use in breast cancer.
引用
收藏
页码：1150 / 1156
页数：7
相关论文
共 50 条
  • [1] PARP inhibitors stumble in breast cancer
    Malini Guha
    Nature Biotechnology, 2011, 29 : 373 - 374
  • [2] PARP INHIBITORS AND FAMILIAL BREAST CANCER
    Mitchell, Gillian
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 86 - 86
  • [3] PARP Inhibitors in Breast and Ovarian Cancer
    Wang, Samuel S. Y.
    Jie, Yeo Ee
    Cheng, Sim Wey
    Ling, Goh Liuh
    Ming, Heong Valerie Yue
    CANCERS, 2023, 15 (08)
  • [4] Update on PARP Inhibitors in Breast Cancer
    Zimmer, Alexandra S.
    Gillard, Mitchell
    Lipkowitz, Stanley
    Lee, Jung-Min
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (05)
  • [5] PARP inhibitors stumble in breast cancer
    Guha, Malini
    NATURE BIOTECHNOLOGY, 2011, 29 (05) : 373 - 374
  • [6] Update on PARP Inhibitors in Breast Cancer
    Alexandra S. Zimmer
    Mitchell Gillard
    Stanley Lipkowitz
    Jung-Min Lee
    Current Treatment Options in Oncology, 2018, 19
  • [7] Clinical efficacy of PARP inhibitors in breast cancer
    Karan Pandya
    Alyssa Scher
    Coral Omene
    Shridar Ganesan
    Shicha Kumar
    Nisha Ohri
    Lindsay Potdevin
    Bruce Haffty
    Deborah L. Toppmeyer
    Mridula A. George
    Breast Cancer Research and Treatment, 2023, 200 : 15 - 22
  • [8] PARP inhibitors and breast cancer: update and perspectives
    Goncalves, Anthony
    BULLETIN DU CANCER, 2012, 99 (04) : 441 - 451
  • [9] Expanding the Use of PARP Inhibitors in Breast Cancer
    Tan, Tira
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (09) : 474 - 477
  • [10] Emerging PARP inhibitors for treating breast cancer
    Robert, Marie
    Patsouris, Anne
    Frenel, Jean-Sebastien
    Gourmelon, Carole
    Augereau, Paule
    Campone, Mario
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (03) : 211 - 221
12345